Cargando...
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3‐TACC3 Fusion and Recurrent Glioblastoma
We describe a case of recurrent glioblastoma treated with anlotinib in this report. The patient was administered anlotinib 12 mg p.o. once every day (days 1–14, with a 21‐day cycle) (anlotinib clinical study NCT04004975) and oral temozolomide chemotherapy 100 mg/m(2) (days 1–7, days 15–21, 28‐day cy...
Guardado en:
| Publicado en: | Oncologist |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930428/ https://ncbi.nlm.nih.gov/pubmed/32949176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13530 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|